REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $35.27.

Several analysts recently issued reports on the company. Raymond James reiterated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of REGENXBIO in a report on Wednesday, December 11th. Morgan Stanley reiterated an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th.

REGENXBIO Stock Performance

Shares of REGENXBIO stock opened at $7.77 on Monday. The stock’s fifty day moving average is $9.07 and its 200 day moving average is $10.77. The stock has a market cap of $384.96 million, a P/E ratio of -1.54 and a beta of 1.28. REGENXBIO has a one year low of $7.14 and a one year high of $28.80.

Institutional Trading of REGENXBIO

A number of hedge funds and other institutional investors have recently bought and sold shares of RGNX. FMR LLC increased its stake in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the period. nVerses Capital LLC increased its position in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the period. GAMMA Investing LLC raised its stake in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,510 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 3,720 shares during the period. Finally, Arizona State Retirement System grew its stake in REGENXBIO by 20.6% in the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 1,997 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.